{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:50:13Z","timestamp":1781668213860,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13555-021-00638-1","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T03:02:27Z","timestamp":1637550147000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52\u00a0Weeks"],"prefix":"10.1007","volume":"12","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-8164","authenticated-orcid":false,"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"638_CR1","doi-asserted-by":"publisher","first-page":"204062232110029","DOI":"10.1177\/20406223211002979","volume":"12","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, de Bruin-Weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021;12:20406223211002980.","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"638_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1185\/030079908X280419","volume":"24","author":"ZD Draelos","year":"2008","unstructured":"Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24(4):985\u201394.","journal-title":"Curr Med Res Opin"},{"issue":"14","key":"638_CR3","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111(14):5147\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"638_CR4","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"638_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"638_CR6","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204.","journal-title":"Allergy"},{"issue":"2","key":"638_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139.","journal-title":"N Engl J Med"},{"issue":"10013","key":"638_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40\u201352.","journal-title":"Lancet"},{"issue":"24","key":"638_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10086","key":"638_CR10","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase\u00a03 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"5","key":"638_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"issue":"2","key":"638_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131\u201343.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"638_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40257-019-00478-y","volume":"21","author":"AS Paller","year":"2020","unstructured":"Paller AS, Bansal A, Simpson EL, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119\u201331.","journal-title":"Am J Clin Dermatol"},{"issue":"26","key":"638_CR14","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"638_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469\u201379.","journal-title":"JAMA"},{"issue":"1","key":"638_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","volume":"158","author":"I Hirano","year":"2020","unstructured":"Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-22.e10.","journal-title":"Gastroenterology"},{"issue":"1","key":"638_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/bjd.17703","volume":"181","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol. 2019;181(1):196\u20137.","journal-title":"Br J Dermatol"},{"key":"638_CR18","unstructured":"Dalia Y, Johnson SM. Case report: first reported case of facial rash after dupilumab therapy. Pract Dermatol. 2018;25\u20136."},{"issue":"11","key":"638_CR19","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","volume":"155","author":"A Soria","year":"2019","unstructured":"Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312\u20135.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"638_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","volume":"155","author":"GA Zhu","year":"2019","unstructured":"Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(7):850\u20132.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"638_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","volume":"5","author":"FSA de Beer","year":"2019","unstructured":"de Beer FSA, Bakker DS, Haeck I, et al. Dupilumab facial redness: positive effect of itraconazole. JAAD Case Rep. 2019;5(1):888\u201391.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"638_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.18730","volume":"183","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"638_CR23","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.jaad.2020.06.1003","volume":"83","author":"S Muzumdar","year":"2020","unstructured":"Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant-Kels JM. Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. J Am Acad Dermatol. 2020;83(5):1520\u20131.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"638_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","volume":"82","author":"RA Waldman","year":"2020","unstructured":"Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"638_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jdcr.2019.12.002","volume":"6","author":"SJ Igelman","year":"2020","unstructured":"Igelman SJ, Na C, Simpson EL. Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep. 2020;6(2):139\u201340.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"638_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/jcm9041241","volume":"9","author":"T Quint","year":"2020","unstructured":"Quint T, Brunner PM, Sinz C, et al. Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis. J Clin Med. 2020;9(4):1241.","journal-title":"J Clin Med"},{"issue":"2","key":"638_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/pde.14499","volume":"38","author":"CE Bax","year":"2021","unstructured":"Bax CE, Khurana MC, Treat JR, Castelo-Soccio L, Rubin AI, McMahon PJ. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatr Dermatol. 2021;38(2):390\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"638_CR28","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"638_CR29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","volume":"4","author":"R Suresh","year":"2018","unstructured":"Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Rep. 2018;4(9):899\u2013904.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"638_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group Exp Dermatol. 2001;10(1):11\u20138.","journal-title":"EASI Evaluator Group Exp Dermatol"},{"key":"638_CR31","doi-asserted-by":"publisher","unstructured":"Barbarot S, Wollenberg A, Silverberg JI, et al. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase\u00a03 trials. J Dermatolog Treat. 2020;1\u201312. https:\/\/doi.org\/10.1080\/09546634.2020.1750550.","DOI":"10.1080\/09546634.2020.1750550"},{"issue":"10","key":"638_CR32","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/jdv.13689","volume":"30","author":"JG Holm","year":"2016","unstructured":"Holm JG, Agner T, Clausen M-L, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"638_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1600-0536.1994.tb02002.x","volume":"31","author":"J Tada","year":"1994","unstructured":"Tada J, Toi Y, Arata J. Atopic dermatitis with severe facial lesions exacerbated by contact dermatitis from topical medicaments. Contact Dermatitis. 1994;31(4):261\u20133.","journal-title":"Contact Dermatitis"},{"key":"638_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40521-014-0028-7","volume":"1","author":"S Pootongkam","year":"2014","unstructured":"Pootongkam S, Nedorost S. Allergic contact dermatitis in atopic dermatitis. Curr Treat Options Allergy. 2014;1:329\u201336.","journal-title":"Curr Treat Options Allergy"},{"issue":"2","key":"638_CR35","first-page":"135","volume":"79","author":"JD Ference","year":"2009","unstructured":"Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135\u201340.","journal-title":"Am Fam Physician"},{"issue":"3","key":"638_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","volume":"72","author":"T Hajar","year":"2015","unstructured":"Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-9.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"638_CR37","first-page":"67","volume":"48","author":"JZ Litt","year":"1993","unstructured":"Litt JZ. Steroid-induced rosacea. Am Fam Physician. 1993;48(1):67\u201371.","journal-title":"Am Fam Physician"},{"issue":"1","key":"638_CR38","first-page":"1","volume":"32","author":"HD Heibel","year":"2019","unstructured":"Heibel HD, Hendricks AJ, Foshee JP, Shi VY. Rosacea associated with dupilumab therapy. J Dermatolog Treat. 2019;32(1):1\u201312.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00638-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00638-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T03:13:48Z","timestamp":1642734828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00638-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00638-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}